PCR Course webcasts, videos & slides

An increasingly proven re-positionable TAVI device offering a true alternative today? Join M. Götberg, T. Feldman and L. Sondergaard as they discuss emerging results from a recent key international trial underlining the safety, efficacy and non-inferiority of the Lotus valve in a high-risk population. Listen as they tease out the meaning behind these results concerning stroke, paravalvular leak and pacemaker use in high- and lower-risk groups. What are we seeing in the newer-generation Lotus device and what design enhancements are we looking for in the future? How important is experience in implantation techniques? What should we expect from upcoming trials? Watch now...

Chairpersons: M.K.Y. Lee , R. Waksman

Objectives: To learn how Magmaris affects thrombogenicity, to discuss on the best implantation techniques, to review optimal indications and patient selection for Magmaris use

Why has this been called “the year” of Left Main interventions? A. Latib, O. Mendiz and Z. Ghazzal review the new maturity of an intervention which pioneer A. Grüntzig attempted years ago. Learn about the compelling data today from the EXCEL study showing non-inferiority of the endovascular approach and discover what is unique about the ongoing European Bifurcation Club’s EBC Main trial. Find out how these studies can impact on indications and eventual changes in future guidelines. From new devices – sizes and the choice of 1 or 2 stents – to experience and improved techniques, the critical elements of strategy and the choice of imaging for planning, optimisation and outcome: you’ll find the details here…

A new “workhorse” drug-eluting stent? Join A. Lansky and A. Baumbach as they discuss what sets the Firehawk apart from other stents available today. Learn why this ultra-thin, cobalt-chromium device, with its abluminal groove and bioresorbable polymer is unique. How this allows the stent a highly targeted delivery, allowing for a reduced drug presence. Learn about the speed of drug elution or the 5-year data from the Chinese experience. Find out about the ongoing European, all-comers non-inferiority trial further exploring the long-term efficacy and safety of this truly innovative device. What are the early results – and the promise for the future? Watch here…

Chairpersons: K.H. Kuck, A. Vahanian

Objectives:To understand how to perform mitral valve repair in patients with functional mitral regurgitation, to understand early results of a clinical programme to perform tricuspid valve repair in patients with tricuspid regurgitation, to learn more about the experience with the Cardioband procedure

Considering the growing epidemic of diabetes mellitus, and the need for effective devices, can we improve clinical outcomes through innovative technologies? Join R. Mehran as she speaks with R. Romaguera and S. Banai and learn why physicians should consider the latest DES technology to make PCI the preferred option rather than CABAGE in diabetics patients. Then discover the Cre8 EVO, its exclusive abluminal reservoirs, unique formulation and EvenArt architecture. Find out about new clinical data, upcoming trials and why this is proving effectiveness…watch now!

Consult this session on the transcatheter treatment of mitral regurgitation if you want to learn more about mitral valve anatomy and the implications for percutaneous treatment of mitral regurgitation, understand the importance of echocardiography in device selection and appreciate the advantages and disadvantages of different percutaneous treatment options.

A new transfemoral TAVI device? What makes the self-expanding ACURATE neo™ different from other available valves? Join S. Redwood, S. Toggweiler and H. Moellmann as they spotlight a system that allows for a unique “top-down” deployment along with stable positioning – what is the significance? Are there advantages using this supra-annular valve? What about data from the SAVI-TF 1000 registry, its endpoints and “compelling” results in high-risk patients and pacemaker rates? How does this compare with other valves and how will a new iteration in development today, the Advance Neo, effect regurgitation? Watch now…

Chairpersons: C. Di Mario , P.W. Serruys

Objectives: To learn about the primary outcomes from DEFINE-FLAIR and iFR-SWEDEHEART, to learn how upcoming iFR studies will address physiology guidance in multivessel disease and entire vessel assessment, to learn how iFR co-registration simplifies complex coronary intervention

Bioresorbable scaffolds have been with us for 10 years, many patients have received these devices successfully and required no other treatment, but questions remain. Where do we stand today concerning outcomes, safety, implant technique or DAPT? How do we approach patient or lesion selection? Is ACS an “attractive” area for BRS? Bifurcations? Long lesions or small vessels? CTO? What data do we have? And what is PSP? The future of BRS? Find out when S. Petronio and N. E. J. West join D. Dudek in this illuminating discussion…